A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland

DSpace/Manakin Repository

A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland

Citable link to this page

 

 
Title: A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland
Author: Pakula, Hubert; Xiang, Dongxi; Li, Zhe

Note: Order does not necessarily reflect citation order of authors.

Citation: Pakula, Hubert, Dongxi Xiang, and Zhe Li. 2017. “A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.” Cancers 9 (2): 14. doi:10.3390/cancers9020014. http://dx.doi.org/10.3390/cancers9020014.
Full Text & Related Files:
Abstract: Prostate cancer (PCa) is one of the most common cancers and among the leading causes of cancer deaths for men in industrialized countries. It has long been recognized that the prostate is an androgen-dependent organ and PCa is an androgen-dependent disease. Androgen action is mediated by the androgen receptor (AR). Androgen deprivation therapy (ADT) is the standard treatment for metastatic PCa. However, almost all advanced PCa cases progress to castration-resistant prostate cancer (CRPC) after a period of ADT. A variety of mechanisms of progression from androgen-dependent PCa to CRPC under ADT have been postulated, but it remains largely unclear as to when and how castration resistance arises within prostate tumors. In addition, AR signaling may be modulated by extracellular factors among which are the cysteine-rich glycoproteins WNTs. The WNTs are capable of signaling through several pathways, the best-characterized being the canonical WNT/β-catenin/TCF-mediated canonical pathway. Recent studies from sequencing PCa genomes revealed that CRPC cells frequently harbor mutations in major components of the WNT/β-catenin pathway. Moreover, the finding of an interaction between β-catenin and AR suggests a possible mechanism of cross talk between WNT and androgen/AR signaling pathways. In this review, we discuss the current knowledge of both AR and WNT pathways in prostate development and tumorigenesis, and their interaction during development of CRPC. We also review the possible therapeutic application of drugs that target both AR and WNT/β-catenin pathways. Finally, we extend our review of AR and WNT signaling to the mammary gland system and breast cancer. We highlight that the role of AR signaling and its interaction with WNT signaling in these two hormone-related cancer types are highly context-dependent.
Published Version: doi:10.3390/cancers9020014
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332937/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071974
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters